Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Current Taxes (2016 - 2020)

Historic Current Taxes for Myriad Genetics (MYGN) over the last 7 years, with Q2 2020 value amounting to $6.1 million.

  • Myriad Genetics' Current Taxes rose 10333.33% to $6.1 million in Q2 2020 from the same period last year, while for Jun 2020 it was $6.1 million, marking a year-over-year increase of 10333.33%. This contributed to the annual value of $6.1 million for FY2020, which is 10333.33% up from last year.
  • Per Myriad Genetics' latest filing, its Current Taxes stood at $6.1 million for Q2 2020, which was up 10333.33% from $3.5 million recorded in Q1 2020.
  • Myriad Genetics' 5-year Current Taxes high stood at $9.8 million for Q3 2018, and its period low was $2.3 million during Q1 2016.
  • Moreover, its 5-year median value for Current Taxes was $3.6 million (2019), whereas its average is $4.6 million.
  • Per our database at Business Quant, Myriad Genetics' Current Taxes surged by 16875.0% in 2017 and then tumbled by 3943.66% in 2018.
  • Quarter analysis of 5 years shows Myriad Genetics' Current Taxes stood at $3.0 million in 2016, then rose by 6.67% to $3.2 million in 2017, then soared by 53.12% to $4.9 million in 2018, then decreased by 18.37% to $4.0 million in 2019, then soared by 52.5% to $6.1 million in 2020.
  • Its Current Taxes was $6.1 million in Q2 2020, compared to $3.5 million in Q1 2020 and $4.0 million in Q4 2019.